A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus NabPaclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A study for patients with metastatic Pancreatic Cancer using study drug MM-141 plus NabPaclitaxel and Gemcitabine
Sponsor: Merrimack Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAQ0008
U.S. Govt. ID: NCT02399137
Contact: Gulam Manji MD: 646-317-6085 / gam2140@cumc.columbia.edu
Additional Study Information: This study is for patients with newly discovered metastatic pancreatic cancer. The main purpose of this study is to evaluate whether the combination of MM-141, nabpaclitaxel and gemcitabine works better against tumor cells than nab-paclitaxel and gemcitabine alone in subjects with this pancreatic cancer.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Do you have pancreatic cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Gulam Manji MD
gam2140@cumc.columbia.edu
646-317-6085
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE